2.48
+0.53(+27.18%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
67
First IPO Date
December 10, 2021
| Name | Title | Pay | Year Born |
| Dr. James Qun Xue M.B.A., Ph.D. | Founder, Chairman of the Board, Chief Executive Officer & Member of Strategic Advisory Board | 5.89M | 1970 |
| Mr. Will Wang | Senior Director & Head of Production | 0 | N/A |
| Dr. Jeff Kou Ph.D. | Director and Head of Program Management & Clinical Operations | 0 | N/A |
| Dr. Jason West | Head of Global Gene Therapy Research | 0 | N/A |
| Ms. Qian Ma | General Counsel, Board Secretary & Joint Company Secretary | 0 | N/A |
| Ms. Chris Chen | Vice President of Human Resources | 0 | N/A |
| Dr. Gerald F. Cox M.D., Ph.D. | Chief Development Strategist & Interim Chief Medical Officer | 0 | 1959 |
| Ms. Rebecca Zhang | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Mr. Joe Shen | Senior Vice President | 0 | N/A |
| Ms. Suya Gao | Acting Head of Commercial Operations of Mainland China | 0 | N/A |
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.